The P140K mutant of human O6-methylguani
โ
Lorna B. Woolford; Thomas D. Southgate; Geoffrey P. Margison; Michael D. Milsom;
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 155 KB
The O 6 -methylguanine-DNA-methyltransferase (MGMT) inactivator O 6benzylguanine (O 6 -beG) is currently under clinical investigation as a potential tumour-sensitising agent. In clinical trials its use has been associated with increased myelotoxicity and a reduced maximum tolerated dose (MTD) for BC